Navigation Links
Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures
Date:5/13/2008

Full Clinical Study Initiated Following Success with 8 Patients

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that a group of cardiovascular and thoracic surgeons from the University of Wurzburg, Germany, have used MEDIHONEY(TM) dressings to successfully treat 8 patients with deep sternal wound infections (DSWI), a condition that sometimes arises after open-heart surgeries. The dressings were used in combination with V.A.C.(R) Therapy (KCI, San Antonio, Texas), the largest and fastest growing technology in advanced wound care. Based on the successful results of this observational study, the researchers have initiated a prospective, randomized, controlled study on the influence of MEDIHONEY on the treatment of DSWI.

Derma Sciences CEO Ed Quilty stated, "The results from this initial 8-patient study are very encouraging. DSWI adds significant additional hospitalization costs to median sternotomy and coronary artery bypass grafting (CABG) procedures, and also significantly increases mortality rates in these patients. We believe the addition of MEDIHONEY to these expensive procedures will provide clinicians a cost-effective way to improve outcomes. Additionally, the recent increase in CABG procedures, due to efficacy concerns over less invasive forms of surgery and drug-eluting stent procedures, makes this an attractive and growing target market."

Quilty went on to say, "Use of the V.A.C. in post-surgical applications -- including DSWI -- has been steadily increasing. Overall, this product generates over $1 billion in revenues globally, and is the first true blockbuster in the field of wound care. Gaining acceptance as an adjunct to this therapy will add significantly to the global usage of MEDIHONEY."

The study was published in the proceedings of the 5th Annual Joint Meeting of the German, Austrian, and Swiss Societies for Card
'/>"/>

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... PLYMOUTH MEETING, Pa., July 25 /PRNewswire-FirstC... announced interim Phase 1 safety and,pharmacokine...emine,(MSI-1436), Genaera,s lead drug candidate fo...ring the CBI 4th Annual Obesity Drug Development,S...Vice President,Nonclinical Development, presented...
(Date:7/24/2008)...Pre-Clinical Data Shows Increased Muscle and Blood...imals, Hearts, SUNRISE, Fla., July 24 /PRNewswire...lving the injection of myoblasts modified to expre... into the scar tissue of the,myocardium of rats, w...y,presented at two scientific meetings -- the Inte...
(Date:7/24/2008)... WASHINGTON, July 24 /PRNewswire-USNewswire/ -- He...do not tell the whole story. The small scale,prel...nline in Human,Reproduction, is based on recollect...ntaining soyfoods. "This study is confounded by ma...d with a great deal of,caution," warned Dr. Tammy ...
(Date:7/24/2008)... NEW YORK, July 24 /- Macro...announced results of a Phase 2 clinical trial,invo...lti-center,open-label efficacy and safety study o...eatment of onychomycosis (nail fungus). The compos...mplete cure" defined as,negative mycology (negativ...
Breaking Medicine Technology:Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 2Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 3Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 4Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6Soyfoods Do Not Impact Sperm Count 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Industry Leaders Select Resverlogixs RVX 208 6457 1Industry Leaders Select Resverlogixs RVX 208 6457 2Industry Leaders Select Resverlogixs RVX 208 6457 3Lehigh to lead 249 6M national research center for serious behavior disorders 23603 1Lehigh to lead 249 6M national research center for serious behavior disorders 23603 2Lehigh to lead 249 6M national research center for serious behavior disorders 23603 3Clean Chemical Free Eye Cream Evening Primrose Oil 3A The Puffy Eye Cure 23600 1Clean Chemical Free Eye Cream Evening Primrose Oil 3A The Puffy Eye Cure 23600 2 242 1 Million Lasik Malpractice Settlement Against Celebrity Physician Dr Joseph Dello Russo 23596 1 242 1 Million Lasik Malpractice Settlement Against Celebrity Physician Dr Joseph Dello Russo 23596 2
(Date:7/25/2008)...SNewswire/ -- The following is being,issued by the...ww.newscom.com/cgi-bin/prnh/20080519/DNCLOGO ), M...on Disabilities, and,Bob Kafka, National Organizer...e of John McCain,s appearance via satellite at the...Ohio. There is speculation that Senator,McCain wil...
(Date:7/25/2008)...arter financial results -, LAVAL, QC, July 25 /PR...SDAQ: DDSS) today announced that it will host a co...) to discuss its second quarter 2008,financial res...8 financial,results via news release at approximat...ence call by telephone, dial 416-646-3095 or,1-800...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...e American Society for Gastrointestinal Endoscopy ...opy in the bariatric surgery patient. The rising p...success in surgical interventions led to a marked ...rformed in the U.S., from 13,365 in 1998 to 102,79... preoperative patient and the postoperative patien...
Breaking Medicine News(10 mins):Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...illion women in the United States undergo breast b...umps are benign, //or non-cancerous. But that beni...ne technique is making it easier for women to get ...t cases, benign breast tumors can be left alone. H...
...the final stages of pregnancy seems to increase th...searchers say a diet rich in fish // may boost the...e more fish a woman ate, the less likely she was t...earchers say that low birth weight normally occurs...
...ividuals in lower socioeconomic groups, as measure...ys than those with // higher socioeconomic status,...impact on their health. While those with more educ... not as affected by it. For the study, more than 1...
...h, there is a link between certain types of beddin...recent study show // an association between freque...electric blankets. For the study, synthetic pillow...olyester or Dacron. Quilts of Dacron, polyester or...
Other Medicine News:
...ut patients negative for antinuclear antibodies, w...c diseases such as Systemic lupus erythematosus (L...disease, progressive systemic sclerosis, scleroder...henomenon. They can also be used in conjunction wi...
The PANBIO Inc. Indirect Fluorescence Assay (IFA) for IgG Antinuclear Antibody (ANA) HEp2 is intended for the qualitative and semi-quantitative detection of IgG (Immunoglobulin G) antinuclear antibod
The VerifyNow Clopidogrel Assay measures changes in platelet function in response to patients taking Clopidogrel (Plavix). It uses a specific activator for the P2Y12 pathway, which clopidogrel inhibi
The Wide Angle Twin Mag NP combines the performance of two instruments to deliver unequalled power and versatility into the hands of eye care professionals.
Medicine Products: